NCIt definition : An orally available selective inhibitor of the epidermal growth factor receptor (EGFR)
mutant form T790M, with potential antineoplastic activity. Upon administration, firmonertinib
specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily
acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads
to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase
that is mutated in many tumor cell types, plays a key role in tumor cell proliferation
and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may
have therapeutic benefits in tumors with T790M-mediated drug resistance.;
UNII : A49A7A5YN4;
CAS number : 1869057-83-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1869057-83-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)